Lupus Science & Medicine

Papers
(The TQCC of Lupus Science & Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
2021 DORIS definition of remission in SLE: final recommendations from an international task force104
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials50
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways37
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies34
Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to ac30
Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials29
SARS-CoV-2 vaccines in patients with SLE29
Living with systemic lupus erythematosus in 2020: a European patient survey29
Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review26
Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review26
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis25
High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus25
Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis21
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria20
Herpes zoster in SLE: prevalence, incidence and risk factors20
Impact of COVID-19 pandemic on SLE: beyond the risk of infection20
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis19
Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–201519
Phenotypical changes and clinical significance of CD4+/CD8+T cells in SLE19
Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus19
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data19
Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries19
Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis18
Towards a practical management of fatigue in systemic lupus erythematosus18
Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease18
Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study18
Associations of metabolic syndrome in SLE17
LLDAS is an attainable treat-to-target goal in childhood-onset SLE17
Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus17
Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus15
Discoid lupus erythematosus skin lesion distribution and characteristics in Black patients: a retrospective cohort study15
Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus15
Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway14
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study14
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus14
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus14
High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index14
Overcoming barriers to recruitment and retention of African–American women with SLE in behavioural interventions: lessons learnt from the WELL study14
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes14
Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE13
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms13
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis13
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis13
Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus12
Loss of antiphospholipid antibody positivity post-thrombosis in SLE12
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE12
Infection hospitalisation in systemic lupus in Sweden12
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica12
Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–201512
Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations11
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus11
Clinical and histopathological features of myositis in systemic lupus erythematosus11
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis11
Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort11
Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial11
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?11
Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre11
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen11
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study11
TNIP1/ABIN1 and lupus nephritis: review10
Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study10
ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases10
Atherosclerosis in SLE: a potential role for serum parathormone levels10
Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016–201810
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus10
Jaccoud-type lupus arthropathy: practical classification criteria9
Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need9
Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies9
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study9
Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus9
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis9
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus9
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis8
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients8
Impact of severe infections in SLE: an observational study from the Spanish national registry8
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort8
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study8
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE8
Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus8
LUPUS-BEST—treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial8
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus8
Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis8
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin8
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)8
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE8
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research8
0.025163173675537